Randomized, multicentre, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bictegravir/ emtricitabine/tenofovir alafenamide in people with HIV, good virological control and neuropsychiatric comorbidities: Week 24 results from the GESIDA 11920 - MIND study

Authors
Category Primary study
ConferenceHIV Glasgow 2024
Year 2024
This article has no abstract
Epistemonikos ID: 129bf793a3e679c4c0257fa440622e7c532cb36e
First added on: Feb 16, 2026